BioMarin prices $850M 5.500% notes due 2034 and syndicates $2B term loan for Amicus acquisition

BIOMARIN PHARMACEUTICAL INC

$850M 5.500% senior notes due 2034; price 100%; expected close Feb 12, 2026.
Syndicated $2B term loan B, plus $800M term loan A and $600M revolver for pending Amicus acquisition.
Proceeds from notes and term loans, plus cash on hand, to fund Amicus acquisition consideration and fees.
If acquisition not completed by Dec 19, 2026, notes subject to special mandatory redemption at 100% plus accrued interest.
Notes guaranteed by BioMarin subsidiaries including Amicus post-closing; covenants limit debt, dividends, liens.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.